Dark Forest Capital Management LP Has $259,000 Stock Position in Axon Enterprise, Inc. (NASDAQ:AXON)

Dark Forest Capital Management LP cut its holdings in shares of Axon Enterprise, Inc. (NASDAQ:AXON) by 45.6% in the 2nd quarter, Holdings Channel reports. The firm owned 880 shares of the biotechnology company’s stock after selling 737 shares during the period. Dark Forest Capital Management LP’s holdings in Axon Enterprise were worth $259,000 at the end of the most recent reporting period.

Other large investors have also recently modified their holdings of the company. ICA Group Wealth Management LLC bought a new stake in shares of Axon Enterprise during the 4th quarter worth $26,000. Blue Trust Inc. grew its stake in shares of Axon Enterprise by 987.5% during the second quarter. Blue Trust Inc. now owns 87 shares of the biotechnology company’s stock worth $27,000 after buying an additional 79 shares during the last quarter. Trivant Custom Portfolio Group LLC acquired a new position in shares of Axon Enterprise during the first quarter worth $31,000. First PREMIER Bank bought a new position in shares of Axon Enterprise in the 1st quarter valued at $33,000. Finally, Rise Advisors LLC boosted its holdings in shares of Axon Enterprise by 49.0% during the 1st quarter. Rise Advisors LLC now owns 143 shares of the biotechnology company’s stock valued at $45,000 after acquiring an additional 47 shares in the last quarter. Institutional investors and hedge funds own 79.08% of the company’s stock.

Wall Street Analyst Weigh In

AXON has been the topic of several research reports. JMP Securities boosted their price target on Axon Enterprise from $375.00 to $430.00 and gave the stock an “outperform” rating in a report on Thursday, September 12th. Barclays boosted their target price on shares of Axon Enterprise from $381.00 to $387.00 and gave the stock an “overweight” rating in a report on Wednesday, August 7th. Needham & Company LLC reaffirmed a “buy” rating and set a $400.00 price target on shares of Axon Enterprise in a research note on Wednesday, August 7th. Robert W. Baird boosted their price objective on shares of Axon Enterprise from $360.00 to $400.00 and gave the stock an “outperform” rating in a research note on Tuesday, September 10th. Finally, Jefferies Financial Group began coverage on Axon Enterprise in a report on Wednesday, July 17th. They issued a “buy” rating and a $385.00 price objective for the company. Two equities research analysts have rated the stock with a hold rating and thirteen have assigned a buy rating to the company’s stock. According to data from MarketBeat.com, Axon Enterprise currently has an average rating of “Moderate Buy” and a consensus price target of $365.38.

Axon Enterprise Price Performance

AXON opened at $395.34 on Monday. Axon Enterprise, Inc. has a fifty-two week low of $190.01 and a fifty-two week high of $398.74. The firm has a 50-day moving average of $356.27 and a 200 day moving average of $320.16. The company has a debt-to-equity ratio of 0.35, a quick ratio of 2.52 and a current ratio of 2.88. The firm has a market cap of $29.88 billion, a P/E ratio of 115.60, a PEG ratio of 10.55 and a beta of 0.94.

Axon Enterprise (NASDAQ:AXON) last released its earnings results on Tuesday, August 6th. The biotechnology company reported $1.20 earnings per share for the quarter, beating analysts’ consensus estimates of $1.02 by $0.18. The firm had revenue of $504.00 million during the quarter, compared to the consensus estimate of $478.35 million. Axon Enterprise had a net margin of 16.06% and a return on equity of 9.34%. The company’s revenue was up 34.5% compared to the same quarter last year. During the same period in the prior year, the firm earned $0.80 EPS. On average, research analysts expect that Axon Enterprise, Inc. will post 1.79 EPS for the current year.

Insiders Place Their Bets

In other news, Director Michael Garnreiter sold 1,000 shares of the company’s stock in a transaction on Monday, September 16th. The stock was sold at an average price of $380.99, for a total transaction of $380,990.00. Following the transaction, the director now owns 27,259 shares of the company’s stock, valued at approximately $10,385,406.41. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. In other Axon Enterprise news, CFO Brittany Bagley sold 4,338 shares of the business’s stock in a transaction on Thursday, September 12th. The shares were sold at an average price of $378.95, for a total transaction of $1,643,885.10. Following the sale, the chief financial officer now owns 98,825 shares of the company’s stock, valued at approximately $37,449,733.75. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, Director Michael Garnreiter sold 1,000 shares of the stock in a transaction on Monday, September 16th. The stock was sold at an average price of $380.99, for a total value of $380,990.00. Following the sale, the director now owns 27,259 shares in the company, valued at approximately $10,385,406.41. The disclosure for this sale can be found here. Insiders sold 317,981 shares of company stock valued at $115,662,734 over the last ninety days. 6.10% of the stock is currently owned by insiders.

Axon Enterprise Company Profile

Axon Enterprise, Inc develops, manufactures, and sells conducted energy devices (CEDs) under the TASER brand in the United States and internationally. It operates through two segments, Software and Sensors, and TASER. The company also offers hardware and cloud-based software solutions that enable law enforcement to capture, securely store, manage, share, and analyze video and other digital evidence.